• Ekaterina Pazukhina, Margarita Andreeva, Ekaterina Spiridonova, Polina Bobkova, Anastasia Shikhaleva, Yasmin El-Taravi, Mikhail Rumyantsev, Aysylu Gamirova, Anastasiia Bairashevskaia, Polina Petrova, Dina Baimukhambetova, Maria Pikuza, Elina Abdeeva, Yulia Filippova, Salima Deunezhewa, Nikita Nekliudov, Polina Bugaeva, Nikolay Bulanov, Sergey Avdeev, Valentina Kapustina, Alla Guekht, Audrey DunnGalvin, Pasquale Comberiati, Diego G Peroni, Christian Apfelbacher, Jon Genuneit, Luis Felipe Reyes, BrackelCaroline L HCLHDepartment of Pediatric Pulmonology, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, the Netherlands.Department of Pediatrics, Tergooi MC, Hilversum, the Netherlands., Victor Fomin, Andrey A Svistunov, Peter Timashev, Lyudmila Mazankova, Alexandra Miroshina, Elmira Samitova, Svetlana Borzakova, Elena Bondarenko, Anatoliy A Korsunskiy, Gail Carson, Louise Sigfrid, Janet T Scott, Matthew Greenhawt, Danilo Buonsenso, Malcolm G Semple, John O Warner, Piero Olliaro, Dale M Needham, Petr Glybochko, Denis Butnaru, Ismail M Osmanov, Daniel Munblit, and Sechenov StopCOVID Research Team.
• Laboratory of Health Economics, Institute of Applied Economic Studies, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
• Bmc Med. 2022 Jul 6; 20 (1): 244244.

BackgroundPrevious studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors.MethodsProspective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge.ResultsOne thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47).ConclusionsAlthough prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.© 2022. The Author(s).

24 keywords...

hide…